Union Bancaire Privee UBP SA Takes $74.55 Million Position in Danaher Co. (NYSE:DHR)

Union Bancaire Privee UBP SA acquired a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 327,201 shares of the conglomerate’s stock, valued at approximately $74,551,000. Danaher makes up about 1.5% of Union Bancaire Privee UBP SA’s investment portfolio, making the stock its 18th biggest position.

Several other large investors also recently made changes to their positions in the business. Capital Asset Advisory Services LLC increased its holdings in Danaher by 4.2% in the fourth quarter. Capital Asset Advisory Services LLC now owns 10,973 shares of the conglomerate’s stock valued at $2,577,000 after purchasing an additional 440 shares during the last quarter. Blue Trust Inc. boosted its stake in Danaher by 75.7% during the 4th quarter. Blue Trust Inc. now owns 16,615 shares of the conglomerate’s stock worth $3,814,000 after acquiring an additional 7,157 shares during the last quarter. Jamison Private Wealth Management Inc. grew its holdings in Danaher by 1.7% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 9,756 shares of the conglomerate’s stock valued at $2,239,000 after purchasing an additional 159 shares during the period. First Citizens Bank & Trust Co. increased its stake in Danaher by 1.4% in the fourth quarter. First Citizens Bank & Trust Co. now owns 40,422 shares of the conglomerate’s stock valued at $9,279,000 after purchasing an additional 561 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. raised its holdings in Danaher by 3.4% in the fourth quarter. Investment Research & Advisory Group Inc. now owns 5,338 shares of the conglomerate’s stock worth $1,225,000 after purchasing an additional 177 shares during the period. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on DHR. Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. KeyCorp increased their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Citigroup reduced their price target on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $285.55.

Danaher Trading Up 0.1 %

NYSE:DHR opened at $245.95 on Monday. The firm has a fifty day simple moving average of $235.33 and a two-hundred day simple moving average of $253.54. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.